International Clinical Trial: Lutetium-177 (177Lu-ACT319) for fibroblast activation protein (FAP)-expressing pancreatic ductal adenocarcinoma, biliary tract carcinoma and other FAP-expressing solid tumours

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ACTRN12626001201369) titled 'Lutetium-177 (177Lu-ACT319) for fibroblast activation protein (FAP)-expressing pancreatic ductal adenocarcinoma, biliary tract carcinoma and other FAP-expressing solid tumours' on Sept. 28.

Study Type: Interventional

Study Design: Purpose: Treatment Allocation: Non-randomised trial Masking: Open (masking not used) Assignment: Other Type of endpoint: Safety/efficacy

Primary Sponsor: Actithera, Inc.

Condition: FAP-expressing pancreatic ductal adenocarcinoma biliary tract carcinoma Other FAP-expressing solid tumours. FAP-expressing pancreatic ductal adenocarcinoma biliary tract carcinoma Other FAP-expressin...